Importance Additional treatments are needed for heart failure with reduced ejection fraction
(HFrEF). Sodium-glucose cotransporter 2 (SGLT2) inhibitors may be an effective treatment …

Background: In DECLARE-TIMI 58 (Dapagliflozin Effect on Cardiovascular Events–
Thrombolysis in Myocardial Infarction 58), the sodium-glucose cotransporter 2 inhibitor …

Importance Dapagliflozin has been shown to reduce the risk of cardiovascular death or
worsening heart failure (HF) in patients with chronic HF and reduced ejection fraction …

Background: Outcome trials in patients with type 2 diabetes mellitus have demonstrated
reduced hospitalizations for heart failure (HF) with sodium-glucose co-transporter-2 …

Background: Many patients with heart failure and reduced ejection fraction (HFrEF) have
chronic kidney disease that complicates pharmacological management and is associated …

BACKGROUND: Patients with heart failure (HF) have a high burden of symptoms and
physical limitations, regardless of ejection fraction (EF). Whether the benefits of SGLT2 …

Importance Dapagliflozin was recently shown to reduce cardiovascular death or worsening
heart failure (HF) events in patients with HF with mildly reduced or preserved ejection …

Importance Women may respond differently to certain treatments for heart failure (HF) with
reduced ejection fraction (HFrEF) than men. Objective To investigate the efficacy and safety …

Objectives This report describes the baseline clinical profiles and management of DELIVER
(Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction …

Drug therapies for people with heart failure and preserved ejection fraction (HFpEF) are
often limited to diuretics to improve symptoms as no therapies demonstrate a mortality …